EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review

Igor Gomez-Randulfe iD, Helen Lavender, Stefan Symeonides iD, Fiona Blackhall

Therapeutic Advances in Medical Oncology · 2025-01 · 17

DOI: 10.1177/17588359251316988 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 27.02.2025. Verfasst von Igor Gomez-Randulfe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due to factors such as self-tolerance to TAAs and the immunosuppressive tumour microenvironment. Combining cancer vaccines with systemic anticancer therapies (SACTs) offers a promising strategy to improve efficacy. However, the optimal timing and combination with immune checkpoint inhibitors (ICIs) and chemotherapy to enhance immunogenicity are not yet fully understood. This review aims to assess the evidence regarding the immunogenicity of antiviral and anticancer vaccines when combined with SACTs, including chemotherapy and ICIs, with a particular focus on the timing of vaccine administration relative to SACT. Additionally, we evaluate the impact of steroids on immunogenicity. Our findings suggest that the timing of vaccine administration is critical, with improved immunogenic responses observed when vaccines are administered at nadir (15 days post-chemotherapy). Certain chemotherapies, such as low-dose metronomic cyclophosphamide and paclitaxel, demonstrate potential for immunomodulation, enhancing T-cell responses when combined with vaccines. Conversely, steroids may reduce immunogenicity. The combination of ICIs with cancer vaccines shows evidence of a synergistic effect, with concurrent administration generally yielding better outcomes than sequential approaches. Prospective trials exploring various timings and sequences are essential to optimize the efficacy of anticancer vaccines.

Schlagwörter

Stichwörter der Autor:innen

cancer vaccineschemotherapyimmune checkpoint inhibitorsimmunogenicitysystemic anticancer therapiesvaccine timing

Autor:innen und Institutionen

  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Centre for Drug Development, Cancer Research UK, Oxford, UK.
  • Edinburgh Cancer Centre, Edinburgh, UK.
  • Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Withington, Manchester M20 4BX, UK.
  • Division of Cancer Sciences, The University of Manchester, Manchester, UK.

ORCID-Profile: Igor Gomez-Randulfe, Stefan Symeonides

Zitieren

APA

Gomez-Randulfe, I., Lavender, H., Symeonides, S., & Blackhall, F. (2025). Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251316988

Vancouver

Gomez-Randulfe I, Lavender H, Symeonides S, Blackhall F. Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251316988

BibTeX
@article{GomezRandulfe2025,
  author = {Gomez-Randulfe, Igor and Lavender, Helen and Symeonides, Stefan and Blackhall, Fiona},
  title = {Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359251316988}
}
Kostenlos starten →